-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in ITeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.0%
Short Interest in ITeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.0%
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,460,000 shares, a growth of 5.0% from the December 31st total of 1,390,000 shares. Based on an average daily volume of 328,200 shares, the days-to-cover ratio is currently 4.4 days. Currently, 5.1% of the shares of the stock are short sold.
Institutional Trading of iTeos Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in iTeos Therapeutics by 16.0% in the 3rd quarter. BlackRock Inc. now owns 4,317,157 shares of the company's stock worth $82,241,000 after acquiring an additional 595,920 shares during the last quarter. State Street Corp increased its stake in iTeos Therapeutics by 44.8% in the 2nd quarter. State Street Corp now owns 2,478,332 shares of the company's stock worth $51,054,000 after acquiring an additional 766,441 shares during the last quarter. Vanguard Group Inc. increased its position in shares of iTeos Therapeutics by 7.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,751,100 shares of the company's stock valued at $33,358,000 after purchasing an additional 121,514 shares during the last quarter. Candriam S.C.A. increased its position in shares of iTeos Therapeutics by 15.2% during the 2nd quarter. Candriam S.C.A. now owns 787,651 shares of the company's stock valued at $16,225,000 after purchasing an additional 103,839 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of iTeos Therapeutics by 146.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company's stock valued at $11,522,000 after purchasing an additional 332,625 shares during the last quarter.
Get iTeos Therapeutics alerts:iTeos Therapeutics Trading Up 2.1 %
ITOS traded up $0.43 on Tuesday, hitting $20.82. 66,953 shares of the company's stock traded hands, compared to its average volume of 326,153. The company's 50 day simple moving average is $19.83 and its 200-day simple moving average is $20.97. The firm has a market cap of $740.78 million, a price-to-earnings ratio of 2.96 and a beta of 1.38. iTeos Therapeutics has a one year low of $16.21 and a one year high of $37.88.
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. The firm had revenue of $19.49 million during the quarter, compared to the consensus estimate of $42.05 million. As a group, equities analysts anticipate that iTeos Therapeutics will post 2.85 EPS for the current fiscal year.iTeos Therapeutics Company Profile
(Get Rating)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Recommended Stories
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,460,000 shares, a growth of 5.0% from the December 31st total of 1,390,000 shares. Based on an average daily volume of 328,200 shares, the days-to-cover ratio is currently 4.4 days. Currently, 5.1% of the shares of the stock are short sold.
iTeos Therapeutics, Inc.(纳斯达克股票代码:ITOS — Get Rating)在1月份的空头利率大幅增长。截至1月15日,空头利率共计146万股,较12月31日的139万股增长了5.0%。根据328,200股的平均每日成交量,目前天数与覆盖率为4.4天。目前,该股有5.1%的股票被卖空。
Institutional Trading of iTeos Therapeutics
iTeOS Therapeutics 的
A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in iTeos Therapeutics by 16.0% in the 3rd quarter. BlackRock Inc. now owns 4,317,157 shares of the company's stock worth $82,241,000 after acquiring an additional 595,920 shares during the last quarter. State Street Corp increased its stake in iTeos Therapeutics by 44.8% in the 2nd quarter. State Street Corp now owns 2,478,332 shares of the company's stock worth $51,054,000 after acquiring an additional 766,441 shares during the last quarter. Vanguard Group Inc. increased its position in shares of iTeos Therapeutics by 7.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,751,100 shares of the company's stock valued at $33,358,000 after purchasing an additional 121,514 shares during the last quarter. Candriam S.C.A. increased its position in shares of iTeos Therapeutics by 15.2% during the 2nd quarter. Candriam S.C.A. now owns 787,651 shares of the company's stock valued at $16,225,000 after purchasing an additional 103,839 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of iTeos Therapeutics by 146.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company's stock valued at $11,522,000 after purchasing an additional 332,625 shares during the last quarter.
许多大型投资者最近增加了或减少了在该公司的股份。贝莱德公司在第三季度将其在iTeOS Therapeutics的股份增加了16.0%。贝莱德公司在上个季度又收购了595,920股股票后,现在拥有该公司4,317,157股股票,价值82,241,000美元。State Street Corp在第二季度将其在iTeOS Therapeutics的股份增加了44.8%。State Street Corp在上个季度又收购了766,441股股票后,现在拥有该公司股票的2478,332股,价值51,054,000美元。Vanguard Group Inc.在第三季度将其在iTeOS Therapeutics的股票头寸增加了7.5%。Vanguard Group Inc.在上个季度又购买了121,514股股票后,现在拥有该公司1,751,100股股票,价值33,35.8万美元。Candriam S.C.A. 在第二季度将其在iTeOS Therapeutics的股票头寸增加了15.2%。Candriam S.C.A. 在上个季度又购买了103,839股股票后,现在拥有该公司787,651股股票,价值16,225,000美元。最后,摩根大通在第二季度将其在iTeOS Therapeutics的股票头寸增加了146.7%。摩根大通在上个季度又购买了332,625股股票后,现在拥有该公司559,299股股票,价值11,522,000美元。
iTeos Therapeutics Trading Up 2.1 %
iTeos Therapeutics 交易价格上涨
ITOS traded up $0.43 on Tuesday, hitting $20.82. 66,953 shares of the company's stock traded hands, compared to its average volume of 326,153. The company's 50 day simple moving average is $19.83 and its 200-day simple moving average is $20.97. The firm has a market cap of $740.78 million, a price-to-earnings ratio of 2.96 and a beta of 1.38. iTeos Therapeutics has a one year low of $16.21 and a one year high of $37.88.
ITOS周二上涨0.43美元,至20.82美元。该公司股票交易量为66,953股,而平均交易量为326,153股。该公司的50天简单移动平均线为19.83美元,其200天简单移动平均线为20.97美元。该公司的市值为7.4078亿美元,市盈率为2.96,beta为1.38。iTeos Therapeutics创下了16.21美元的一年低点,为37.88美元。
iTeos Therapeutics Company Profile
iTeos Therapeutic
(Get Rating)
(获取评分)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Iteos Therapeutics, Inc是一家临床阶段的生物制药公司,从事患者免疫肿瘤疗法的发现和开发。该公司的产品线包括 inupadenant,一种正在进行第 2 期临床试验的腺苷 A2AR 拮抗剂的小分子拮抗剂;以及 EOS-448,一种具有 Ig 和 ITIM 结构域的 TIGIT 或 T 细胞免疫受体的拮抗剂,正处于 1/2 期临床试验,用于与 Fc 伽玛受体或 Fc?R 激活树突状细胞和巨噬细胞,促进抗体依赖性细胞毒性或 ADCC 活性。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
- 免费获取 StockNews.com 关于 iTEOS Therapeutics (ITOS) 的研究报告的副本
- Verizon、Charter在过去一个月中呈上升趋势:他们现在买了吗?
- 股息之王 Sysco:逢低买入
- Genius集团股票上涨1,600%是否合理?
- 经过进一步审查,投资者喜欢埃克森美孚的收益
- 卡特彼勒会挖掘另一个买入机会吗?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 iTeOS Therapeutics 每日的新闻和评 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收iTeOS Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧